Homocysteine, a Risk Factor for Cardiovascular Disease

Area of Science:

• Cardiovascular Science
• Vascular Biology
• Metabolic Disease

Background:

• Fasting hyperhomocysteinemia is an independent risk factor for cardiovascular diseases, including coronary artery disease, stroke, and peripheral vascular atherosclerosis.
• The risk associated with elevated homocysteine levels is comparable to traditional risk factors like hypertension and smoking.
• Homocysteine contributes to atherosclerosis, thromboembolism, and vascular endothelial cell injury, potentially through oxidative stress and impaired nitric oxide production.

Purpose of the Study:

• To review the role of hyperhomocysteinemia as a risk factor for vascular diseases.
• To explore the mechanisms by which homocysteine induces vascular damage.
• To highlight the efficacy of B vitamins in managing homocysteine levels.

Main Methods:

• Review of existing literature on hyperhomocysteinemia and vascular disease.
• Analysis of studies investigating the mechanisms of homocysteine-induced endothelial dysfunction.
• Evaluation of clinical trials on the effects of B vitamin supplementation on homocysteine levels.

Main Results:

• Hyperhomocysteinemia significantly increases the risk of arterial and venous thromboembolism.
• Homocysteine-induced vascular dysfunction is linked to endothelial cell injury, smooth muscle cell proliferation, and oxidative stress.
• Folic acid, vitamin B12, and vitamin B6 supplementation demonstrably reduce plasma homocysteine levels.
• Folic acid is particularly effective, safe, and cost-efficient for lowering homocysteine.

Conclusions:

• Hyperhomocysteinemia is a critical, modifiable risk factor for a spectrum of vascular pathologies.
• Understanding homocysteine's detrimental effects on the vasculature is crucial for cardiovascular risk assessment.
• B vitamin supplementation, especially folic acid, offers a viable therapeutic strategy to mitigate homocysteine-related vascular risks.